242 related articles for article (PubMed ID: 25691062)
1. Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells.
Das S; Rachagani S; Torres-Gonzalez MP; Lakshmanan I; Majhi PD; Smith LM; Wagner KU; Batra SK
Oncotarget; 2015 Mar; 6(8):5772-87. PubMed ID: 25691062
[TBL] [Abstract][Full Text] [Related]
2. Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi/post-Golgi compartments.
Das S; Majhi PD; Al-Mugotir MH; Rachagani S; Sorgen P; Batra SK
Sci Rep; 2015 Jun; 5():9759. PubMed ID: 26044153
[TBL] [Abstract][Full Text] [Related]
3. MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion.
Marimuthu S; Lakshmanan I; Muniyan S; Gautam SK; Nimmakayala RK; Rauth S; Atri P; Shah A; Bhyravbhatla N; Mallya K; Grandgenett PM; Hollingsworth MA; Datta K; Jain M; Ponnusamy MP; Batra SK
Mol Cancer Res; 2022 Aug; 20(8):1208-1221. PubMed ID: 35533267
[TBL] [Abstract][Full Text] [Related]
4. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.
Thériault C; Pinard M; Comamala M; Migneault M; Beaudin J; Matte I; Boivin M; Piché A; Rancourt C
Gynecol Oncol; 2011 Jun; 121(3):434-43. PubMed ID: 21421261
[TBL] [Abstract][Full Text] [Related]
5. MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells.
Lakshmanan I; Ponnusamy MP; Das S; Chakraborty S; Haridas D; Mukhopadhyay P; Lele SM; Batra SK
Oncogene; 2012 Feb; 31(7):805-17. PubMed ID: 21785467
[TBL] [Abstract][Full Text] [Related]
6. MUC16 facilitates cervical cancer progression via JAK2/STAT3 phosphorylation-mediated cyclooxygenase-2 expression.
Shen H; Guo M; Wang L; Cui X
Genes Genomics; 2020 Feb; 42(2):127-133. PubMed ID: 31736008
[TBL] [Abstract][Full Text] [Related]
7. MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism.
Shukla SK; Gunda V; Abrego J; Haridas D; Mishra A; Souchek J; Chaika NV; Yu F; Sasson AR; Lazenby AJ; Batra SK; Singh PK
Oncotarget; 2015 Aug; 6(22):19118-31. PubMed ID: 26046375
[TBL] [Abstract][Full Text] [Related]
8. MUC16 Regulates TSPYL5 for Lung Cancer Cell Growth and Chemoresistance by Suppressing p53.
Lakshmanan I; Salfity S; Seshacharyulu P; Rachagani S; Thomas A; Das S; Majhi PD; Nimmakayala RK; Vengoji R; Lele SM; Ponnusamy MP; Batra SK; Ganti AK
Clin Cancer Res; 2017 Jul; 23(14):3906-3917. PubMed ID: 28196872
[No Abstract] [Full Text] [Related]
9. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC).
Liu L; Xiang J; Chen R; Fu D; Hong D; Hao J; Li Y; Li J; Li S; Mou Y; Mai G; Ni Q; Peng L; Qin R; Qian H; Shao C; Sun B; Sun Y; Tao M; Tian B; Wang H; Wang J; Wang L; Wang W; Wang W; Zhang J; Zhao G; Zhou J; Yu X;
Int J Oncol; 2016 Mar; 48(3):900-7. PubMed ID: 26718269
[TBL] [Abstract][Full Text] [Related]
10. Pathobiological implications of MUC16 expression in pancreatic cancer.
Haridas D; Chakraborty S; Ponnusamy MP; Lakshmanan I; Rachagani S; Cruz E; Kumar S; Das S; Lele SM; Anderson JM; Wittel UA; Hollingsworth MA; Batra SK
PLoS One; 2011; 6(10):e26839. PubMed ID: 22066010
[TBL] [Abstract][Full Text] [Related]
11. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation.
Chen SH; Hung WC; Wang P; Paul C; Konstantopoulos K
Sci Rep; 2013; 3():1870. PubMed ID: 23694968
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma.
Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Xu J; Yu X
Mol Cancer Res; 2017 Feb; 15(2):201-212. PubMed ID: 28108627
[TBL] [Abstract][Full Text] [Related]
13. Mucin 16 Promotes Colorectal Cancer Development and Progression Through Activation of Janus Kinase 2.
Liu Z; Gu Y; Li X; Zhou L; Cheng X; Jiang H; Huang Y; Zhang Y; Xu T; Yang W; Huang Q
Dig Dis Sci; 2022 Jun; 67(6):2195-2208. PubMed ID: 33982216
[TBL] [Abstract][Full Text] [Related]
14. MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer.
Fan K; Yang C; Fan Z; Huang Q; Zhang Y; Cheng H; Jin K; Lu Y; Wang Z; Luo G; Yu X; Liu C
Cancer Lett; 2018 Apr; 418():167-175. PubMed ID: 29337110
[TBL] [Abstract][Full Text] [Related]
15. MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR.
Chaudhary S; Appadurai MI; Maurya SK; Nallasamy P; Marimuthu S; Shah A; Atri P; Ramakanth CV; Lele SM; Seshacharyulu P; Ponnusamy MP; Nasser MW; Ganti AK; Batra SK; Lakshmanan I
Breast Cancer Res; 2023 Mar; 25(1):25. PubMed ID: 36918912
[TBL] [Abstract][Full Text] [Related]
16. DUSP28 links regulation of Mucin 5B and Mucin 16 to migration and survival of AsPC-1 human pancreatic cancer cells.
Lee J; Lee J; Yun JH; Jeong DG; Kim JH
Tumour Biol; 2016 Sep; 37(9):12193-12202. PubMed ID: 27230679
[TBL] [Abstract][Full Text] [Related]
17. C-terminus of MUC16 activates Wnt signaling pathway through its interaction with β-catenin to promote tumorigenesis and metastasis.
Liu Q; Cheng Z; Luo L; Yang Y; Zhang Z; Ma H; Chen T; Huang X; Lin SY; Jin M; Li Q; Li X
Oncotarget; 2016 Jun; 7(24):36800-36813. PubMed ID: 27167110
[TBL] [Abstract][Full Text] [Related]
18. REG3A accelerates pancreatic cancer cell growth under IL-6-associated inflammatory condition: Involvement of a REG3A-JAK2/STAT3 positive feedback loop.
Liu X; Wang J; Wang H; Yin G; Liu Y; Lei X; Xiang M
Cancer Lett; 2015 Jun; 362(1):45-60. PubMed ID: 25779676
[TBL] [Abstract][Full Text] [Related]
19. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract][Full Text] [Related]
20. MUC16: molecular analysis and its functional implications in benign and malignant conditions.
Haridas D; Ponnusamy MP; Chugh S; Lakshmanan I; Seshacharyulu P; Batra SK
FASEB J; 2014 Oct; 28(10):4183-99. PubMed ID: 25002120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
